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Objectives: 1) To estimate the annual cost of patients with stable chronic obstructive pulmonary 
disease (COPD) followed in primary care in Spain; 2) To analyze the possible cost predictor 
variables.
Patients and methods: A multicenter, epidemiological, observational, descriptive study. 
Sociodemographic data, severity of disease, associated comorbidity, treatment followed by 
patients, quality of life (SF-12 questionnaire), health care resource utilization in the previous 
12 months and duration of working disability due to COPD were collected.
Results: A total of 10,711 patients (75.6% men; 24.4% women) with a mean age of 67.1 ± 9.66 
years were evaluated. The mean forced expiratory volume in one second (FEV1) value was 
57.4 ± 13.4%. The total cost per patient per year was  1,922.60 ± 2,306.44. The largest 
component of this cost was hospitalization ( 788.72 ± 1,766.65), followed by cost of drugs 
( 492.87 ± 412.15) and visits to emergency rooms ( 134.32 ± 195.44). Linear regression 
analysis found associated heart disease, FEV1, physical component of quality of  life, number of 
medical visits (primary care physician, pneumologist and emergency room), hospital admissions 
(frequency and duration of stay) and duration of working disability to be signiﬁ  cant predictors 
of the total annual cost.
Conclusions: The total annual cost of a COPD patient followed in primary care in Spain was 
considered high in this study. The presence of associated heart disease, severity of airﬂ  ow 
obstruction, physical component of quality of life, health care resource utilization and duration 
of work disability were found to be predictor of cost.
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Introduction
Chronic obstructive pulmonary disease (COPD) is one of the most important respira-
tory problems we face today. It is the fourth leading cause of morbidity and mortality 
in the developed world (Pauwels et al 2001). In Spain, COPD affects 9.1% of the 
general population between 40 and 69 years of age (Sobradillo et al 2000), and is 
responsible for approximately 10%–12% of primary care visits and 35%–40% of 
visits to a pneumologist. It also causes 35% of permanent work disabilities and 7% 
of hospital admissions (Pauwels et al 2001; Álvarez-Sala et al 2001). Because of the 
growing morbidity and mortality associated with this disease, it causes a high utili-
zation of health care resources and a large economic burden to society. Thus, it has 
been reported that the expenses caused by this disease in Spain amount by 2% of the 
national health annual budget and 0.25% of the gross domestic product (Álvarez-Sala 
et al 2001). Furthermore, it is predicted that the impact of this disease will increase 
in coming years as a result of the rise in the life expectancy of the population, the 
increase in its prevalence and the emergence of new drugs and treatment modalities. 
Despite this, there are few studies in Spain that have quantiﬁ  ed the costs of COPD 
(Grupo DAFNE 2000; García et al 2003; Miravitlles et al 2003; Izquierdo 2003; International Journal of COPD 2008:3(4) 702
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Izquierdo-Alonso 2004; Masa et al 2004; Sicras Mainar et al 
2007), and they differ in the criteria used for sampling and 
for assessment of the resources consumed. As a result, they 
also differ in the ﬁ  ndings obtained. In addition, most of these 
studies had a small sample size and included patients from 
different care levels.
The primary objective of this study was to estimate the 
annual cost generated by patients with stable COPD followed 
in primary care facilities in Spain. The secondary objective 
was to analyze the possible variables with ability to predict 
the cost of the disease.
Materials and methods
Design and study population
This analysis is part of the EPIDEPOC study, a multicenter, 
epidemiological, observational, descriptive study carried out 
in the primary care setting to estimate the use of health care 
resources and to assess the quality of life of patients with 
stable COPD (Carrasco Garrido et al 2006). The recruitment 
of patients and calculation of sample size corresponded to 
that performed in the EPIDEPOC study (Carrasco Garrido 
et al 2006). For calculation of sample size, a cluster design 
was used, considering 3 types of variables: health centers, 
physicians, and medical records. As the health centers were 
considered to be homogeneous and representative of the 
Spanish geographical population, the medical record was 
chosen as the unit of study and the prescriber as the cluster. 
A previous study in a large cohort of 1,510 primary care 
patients found that the average annual cost per patient varied 
widely, with an estimated standard deviation of  3,407 
(Izquierdo 2003). Assuming a precision of  90, 5,505 medi-
cal records needed to be evaluated. If the effect of the cluster 
design is also taken into account, ie, the loss of efﬁ  cacy from 
the use of clusters, assuming a correlation of 0.3 and a cluster 
size of 5, a total of 2,422 prescribers and 12,111 medical 
records would be required.
Patients were selected consecutively by primary care 
physicians from all Spanish autonomous communities, 
whose distribution was weighted based on the population of 
each community. Patients were recruited during a period 
of 3 months (from January 1 to March 31, 2003). Subjects 
of both sexes, aged 40 years or older, and diagnosed with 
COPD at least 12 months before the start of the study, were 
included. The diagnosis of COPD was performed according 
to the criteria of the Spanish Society of Pneumology and 
Chest Surgery (SEPAR) and was based on demonstration by 
means of forced spirometry of a forced expiratory volume in 
1 second (FEV1) less than 80% of the predicted value and a 
FEV1/forced vital capacity (FVC) ratio less than 0.7 after the 
bronchodilation test. The severity of the disease was classi-
ﬁ  ed into three levels based on the FEV1 value: mild (FEV1 
60%–80% of predicted value), moderate (FEV1 40%–59% of 
predicted value) and severe (FEV1 less than 40% of predicted 
value), in accordance with the SEPAR criteria (Barberà et al 
2001). Patients with a neurological or psychiatric illness 
that would preclude their assessment during the study were 
excluded. Patients with an acute exacerbation of COPD in the 
previous month were also excluded. An acute exacerbation 
was considered to be the occurrence of an impairment of the 
clinical condition of the patient characterized by increased 
baseline dyspnea, purulent sputum, increased volume of 
sputum or any combination of these symptoms.
The study was approved by the Ethics Committee of the 
Alcorcón Hospital Foundation, and all patients gave their 
oral consent to participate in it.
Assessment of patients
A single visit was completed in which sociodemographic 
data, year of COPD diagnosis, severity of the disease, comor-
bidity, and utilization of health care resources in the previous 
12 months was collected. All patients were administered the 
short form 12-item (SF-12) quality of life questionnaire, an 
abbreviated version of the SF-36 health questionnaire (Ware 
et al 1996). These 12 items explain more than 90% of the 
variance of the physical and mental component scores of the 
SF-36. The physical (PCS-12) and mental component sum-
mary (MCS-12) scores are then calculated, using a value of 
50 with a standard deviation of 10 as the reference popula-
tion. The SF-12 is scored from 0 to 100 with higher scores 
indicating better health status.
Direct costs were calculated from the information on the 
different procedures provided by the managements of  Madrid 
Health Area 8 and the Alcorcón and Móstoles Hospitals. 
Indirect costs were calculated using the human capital 
method. This method is based on the assumption that the 
value of the lost production is equal to the wages associated 
with obtaining this production. In other words, a day missed 
from work implies a loss of production equal to the wages 
that would have been earned on that day. The information 
on employment and wages was obtained from the Spanish 
Statistical Ofﬁ  ce.
Statistical analysis
Statistical analysis of the data was carried out using the 
SPSS 12.0 for Windows statistical package (SPSS Inc., 
Chicago, IL). Qualitative variables were described by International Journal of COPD 2008:3(4) 703
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frequency and percentage and quantitative variables by 
mean, standard deviation, minimum and maximum. The 
Pearson χ2 test was used to analyze the relationship between 
qualitative variables. Student’s t test for independent 
measurements was used to calculate the differences in the 
means of the two groups and the ANOVA test to study 
the differences between more than two groups of patients. 
Finally, a multiple linear regression analysis was performed 
using the total annual cost per COPD patient as the dependent 
variable. Variables signiﬁ  cant in the bivariate analysis or 
deemed clinically relevant were included in the model. All 
statistical tests were two-tailed and a value of p  0.05 was 
considered signiﬁ  cant.
Results
The number of physicians participating in the study was 
2,377, which allowed a total of 10,711 patients (75.6% men) 
to be recruited, with a mean age of 67.1 ± 9.66 years. Table 1 
show the sociodemographic and clinical characteristics of the 
sample studied. The mean FEV1 value was 57.4 ± 13.4%. The 
severity of the disease was mild in 35.5% of cases, moderate 
in 53.4% and severe in 11.2%. The most frequent observed 
comorbidities were hypertension (47.7%), hypercholesterol-
emia (41.3%), anxiety (22.2%), heart disease (18.8%), gas-
troduodenal ulcer (17.4%), diabetes (16.9%), and depression 
(12.8%). The mean PCS-12 and MCS-12 scores on the SF-12 
quality of life questionnaire were 35.9 ± 10.3 and 48.2 ± 11.4, 
respectively. The mean number of drugs prescribed to the 
patients was 2.28 ± 1.03. The most frequently prescribed drugs 
were anti-cholinergics (84.8%), followed by short-acting 
β2-agonists (38.9%), inhaled corticoids (22.1%), theophyllines 
(11.8%), long-acting β2-agonists (9.5%), mucolytics (8.9%), 
and oral corticoids (4.6%).
With regard to the use of health care resources in the 
previous year, the mean values were: visits to primary care 
physicians; 6.66 ± 5.71, visits to pneumologists; 1.43 ± 1.52, 
visits to emergency rooms; 1.60 ± 2.71 and hospital admis-
sions; 0.50 ± 1.17 (Table 2). When the possible factors related 
to the use of health care resources were analyzed, a sig-
niﬁ  cant association was found with sex, with a signiﬁ  cantly 
higher number of hospital admissions in men than in women 
(0.53 ± 1.24 versus 0.33 ± 0.93, p  0.001), although there 
were no differences in the number of visits to primary care 
or specialist physicians or in the duration of disability leaves. 
As expected, a statistically signiﬁ  cant association was found 
between the use of health care resources and the age of the 
patients; the older the patient, the more frequent was the use 
of health care resources (Table 3). Finally, a clear association 
was found between the use of health care resources and 
the severity of COPD: patients with a more severe disease 
consumed more health care resources in terms of the number 
of visits to primary care, pneumologist and emergency rooms, 
the number of hospital admissions and duration of work 
disability (Table 4).
The total annual cost per COPD patient was 
1,922.60 ± 2,306.44, with the largest component for 
Table 1 Sociodemographic and clinical characteristics of the 
patients studied
Characteristic (no of patients)
Total no of patients 10711
Age (years)* (8865) 64.1 ± 9.7 (40; 98)
Age groups (8862)
40–54 years 963 (10.9)
55–64 years 2249 (25.4)
65–74 years 3669 (41.4)
75 years 1981 (22.4)
Sex (men) (10,620) 8030 (75.6)
Smoking (10,649)
Never smoked 2468 (23.2)
Ex-smoker 6153 (57.8)
Active smoker 2028 (19.0)
FEV1* (9963) 57.4 ± 13.4
COPD severity (9963)
Mild 3634 (35.5)
Moderate 5471 (53.4)
Severe 1146 (11.2)
Comorbidities
Hypertension (9876) 4706 (47.7)
Diabetes (9453) 1598 (16.9)
Heart disease (9390) 1770 (18.8)
Ulcer (9425) 1637 (17.4)
Depression (9333) 1196 (12.8)
Anxiety (9397) 2084 (19.5)
Treatment
Short-acting β2-adrenergic agonists (10,706) 4165 (38.9)
Long-acting β2-adrenergic agonists (10,610) 1008 (9.5)
Anticholinergics (10,615) 9002 (84.8)
Theophyllines (10,703) 1263 (11.8)
Inhaled corticoids (10,711) 2369 (22.1)
Oral corticoids (10,711) 498 (4.6)
Mucolytics (10,674) 950 (8.9)
Oxygen therapy (10,007) 1351 (13.5)
Notes: * Values expressed as mean ± standard deviation (minimum; maximum) or 
frequencies (percentages).
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced 
expiratory volume in one second.International Journal of COPD 2008:3(4) 704
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hospital admissions ( 788.72 ± 1,766.65), followed by cost 
of drugs ( 492.87 ± 412.15) and cost of visits to emergency 
rooms ( 134.32 ± 195.44, Figure 1). Signiﬁ  cant higher total 
annual costs were found in men than in women (Table 5), 
and in smokers and ex-smokers than in nonsmoker subjects 
(Table 6). Age and severity of disease was also shown to 
be associated with total costs, with differences according 
to gender at different levels of age and severity of disease. 
In men, both factors were found to be independently 
signiﬁ  cant without interaction. In women, only severity of 
COPD was found to be statistically signiﬁ  cant (Figure 2). 
As expected, patients with hospital admissions showed 
higher total annual costs than subjects without admissions 
(Table 7).
Table 2 Health care resource utilization and disability days at work during the year previous to the study
Health care resources and disability 
at work
N Median Mean 95% CI
Primary care physician visits (#) 10,242 5 6.66 6.55 6.77
Pneumologist visits (#) 9897 1 1.43 1.40 1.46
Emergency room visits (#) 9574 1 1.60 1.54 1.65
Hospital admissions (#) 8677 0 0.50 0.48 0.52
Duration of stay (days) 4744 5.6 7.24 6.91 7.57
Duration of disability leave (days) 4984 5.1 8.86 8.21 9.52
Abbreviation: CI, conﬁ  dence interval.
Table 3 Health care resource utilization by age group
N Median Mean 95% CI p
Primary care physicians visits (#):
  – 40–54 years 921 4.00 5.73 (5.42–6.03)
  – 55–64 years 2180 5.00 6.44 (6.20–6.68) 0.001
  – 65–74 years 3525 5.00 6.84 (6.64–7.02)
 –  75 years 1900 6.00 7.35 (7.06–7.63)
Pneumologist visits (#):
  – 40–54 years 887 1.00 1.28 (1.18–1.36)
  – 55–64 years 2106 1.00 1.39 (1.33–1.46) 0.001
  – 65–74 years 3418 1.00 1.45 (1.41–1.50)
 –  75 years 1840 1.00 1.57 (1.48–1.65)
Emergency room visits (#):
  – 40–54 years 865 1.00 1.37 (1.20–1.54)
  – 55–64 years 2039 1.00 1.59 (1.47–1.71) 0.001
  – 65–74 years 3311 1.00 1.62 (1.53–1.71)
 –  75 years 1783 1.00 1.79 (1.65–1.93)
Hospital admissions (#):
  – 40–54 years 769 0.00 0.30 (0.24–0.36)
  – 55–64 years 1828 0.00 0.40 (0.36–0.44) 0.001
  – 65–74 years 3007 0.00 0.52 (0.47–0.57)
 –  75 years 1670 0.00 0.68 (0.62–0.74)
Duration of disability leave (days):
  – 40–54 years 693 8.00 15.60 (13.40–17.81)
  – 55–64 years 1391 7.00 16.44 (14.73–18.14) 0.001
  – 65–74 years 1402 0.34 2.10 (1.62–2.58)
 –  75 years 677 0.00 0.42 (0.22–0.62)
Abbreviation: CI, conﬁ  dence interval.International Journal of COPD 2008:3(4) 705
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Table 4 Health care resource utilization by COPD severity
N Median Mean 95% CI P
Primary care physician visits (#):
  – Mild COPD 3529 4.00 5.15 (5.00–5.30)
  – Moderate COPD 5246 6.00 7.08 (6.92–7.25) 0.001
  – Severe COPD 1096 7.50 9.54 (9.09–9.99)
Pneumologist visits (#):
  – Mild COPD 3369 1.00 1.01 (0.97–1.04)
  – Moderate COPD 5090 1.00 1.52 (1.48–1.56) 0.001
  – Severe COPD 1084 2.00 2.32 (2.19–2.46)
Emergency room visits (#):
  – Mild COPD 3255 0.00 1.01 (0.94–1.08)
  – Moderate COPD 4623 1.00 1.71 (1.63–1.79) 0.001
  – Severe COPD 1057 2.00 2.88 (2.68–3.08)
Hospital admissions (#):
  – Mild COPD 2975 0.00 0.24 (0.20–0.28)
  – Moderate COPD 4406 0.00 0.50 (0.47–0.52) 0.001
  – Severe COPD 1001 1.00 1.33 (1.22–1.44)
Duration of disability leave (days):
  – Mild COPD 1967 4.38 7.22 (6.39–8.05)
  – Moderate COPD 2495 5.69 9.75 (8.77–10.73) 0.001
  – Severe COPD 348 4.48 11.02 (7.27–14.77)
Abbreviations: CI, conﬁ  dence interval; COPD, chronic obstructive pulmonary disease.
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On the other hand, a signiﬁ  cant association between total 
costs and quality of life, as assessed with SF-12 question-
naire, was found with physical and mental components of 
quality of life. Subjects with worse quality of  life showed 
higher costs, independently of gender (Figure 3). This ﬁ  gure 
shows the impact of poorer quality of life on total costs by 
quartiles of physical and mental components according to 
sex: The mental component showed a signiﬁ  cant interaction 
with sex.
Linear regression analysis found associated heart disease, 
FEV1, physical component of quality of life, number of medi-
cal visits (primary care physician, pneumologist and emer-
gency room), hospital admissions (frequency and duration 
of stay) and duration of working disability to be signiﬁ  cant 
predictors of the total annual cost (Table 8).
Discussion
This study showed that the total cost per COPD patient was 
near  2,000 per year when primary care physicians take 
care on these subjects. Concomitant heart disease, reduced 
FEV1, poor physical component of quality of life, increased 
number of medical visits, hospital admissions and incapaci-
tating days for work were found to be explanatory variables 
associated with increased costs. The strength of this study 
lies in the elevated number of patients with stable COPD 
recruited in primary care clinics in Spain, including patients 
with multiple comorbidities, which are usually excluded 
from clinical trials. The study thus reﬂ  ects real-world data. 
It should be taken into account that most Spanish patients 
with COPD are treated by general practitioners and that the 
proportion of patients referred to specialists is lower than in 
other West European countries (Esteban et al 2003).
Previous studies have shown health care total annual cost 
per COPD patient to vary between  1,100 and  3,400, with 
a median cost of about  2,000, a ﬁ  gure that is similar to that 
obtained in our study (Garcia et al 2003; Izquierdo 2003; 
Miravitlles et al 2003; Izquierdo-Alongo et al 2004; Masa 
et al 2004). The distribution of costs found in this study also 
shows considerable agreement with data provided by other 
authors: approximately 40% of the cost is produced by the 
Table 5 Comparison of different component of total costs by gender
Gender N Mean Median 95% CI
Cost of hospitalization Men 8030 828.28* 563.75 (788.75–867.81)
Women 2590 673.62 430.28 (610.77–736.47)
Cost of drugs per year Men 8030 500.30* 529.25 (491.24–509.36)
Women 2590 467.13 365.00 (451.60–482.67)
Cost of visits to emergency 
rooms
Men 8030 136.80* 104.52 (132.49–141.11)
Women 2590 126.59 104.52 (119.30–133.88)
Cost of diagnostic tests Men 8030 131.88* 97.32 (128.61–135.16)
Women 2590 120.35 97.32 (114.89–125.81)
Cost of visits to primary care Men 8030 107.69 83.85 (105.57–109.81)
Women 2590 104.37 83.85 (100.72–108.01)
Cost of oxygen therapy per year Men 8030 101.87* 50.72 (95.17–108.59)
Women 2590 68.20 15.41 (58.32–78.09)
Cost of visits to pneumologists Men 8030 95.58* 70.53 (93.21–97.95)
Women 2590 87.22 70.53 (83.26–91.18)
Cost of disability leave Men 8030 69.02 21.90 (62.67–75.38)
Women 2590 60.18 19.22 (50.33–70.03)
Cost of pneumococcal vaccine Men 8030 4.65 4.36 (4.50–4.80)
Women 2590 4.38 4.05 (4.12–4.64)
Cost of inﬂ  uenza vaccine Men 8030 0.20* 0.00 (0.18–0.21)
Women 2590 0.23 0.00 (0.21–0.25)
Total annual cost per COPD 
patient
Men 8030 1989.20* 1112.20 (1937.48–2040.93)
Women 2590 1724.53 984.23 (1643.35–1805.71)
Note: *p  0.05 between sexes, differences between means not signiﬁ  cant when not stated.
Abbreviations: CI, conﬁ  dence interval; COPD, chronic obstructive pulmonary disease.International Journal of COPD 2008:3(4) 707
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hospitalization component, which represents the largest 
proportion of the cost. Second most important component in 
term of cost was drug costs, which in our study represented 
almost 26% of the total expenses, being this value lower 
than that obtained in other studies. These differences might 
be explained by the greater severity of the patients included 
in our study. Thus, it has been shown an interaction between 
severity of disease and components of cost; as the severity of 
the disease increases, not only does the cost increase, but the 
distribution of costs changes as could be expected to some 
extend. Hence, hospital stay costs increase with severity of 
disease, and at the same time drug costs are reduced. In this 
way, a recent study carried out in our setting showed that 
drug therapy accounted for 43% of total direct costs in mild 
COPD, but that this percentage decreased to 37.6% and 
28.4% in moderate and severe stages, respectively (Izquierdo 
Alonso et al 2004).
The reduction of lung function in COPD patients is 
associated with a higher number of cardiovascular events 
and deaths from a cardiac cause, although the mechanisms 
responsible for this association are not well known. 
A relationship between COPD and cardiovascular diseases, 
linked to a systemic inﬂ  ammatory component, has been 
observed even in patients with mild or moderate obstruc-
tion (Villar Álvarez et al 2008). This study showed that the 
prevalence of heart disease associated with COPD was high 
(18.8%), and that it was one of the major determinants of 
the overall cost of the disease. These results contrast with 
those obtained in a recent study with a similar prevalence 
of cardiovascular events, in which no differences were 
observed in the annual cost per patient according to the 
presence or absence of these events (Sicras Mainar et al 
2007). The authors of this study noted that certain limitations 
of the study require caution when generalizing the results, 
such as the design of the study itself, possible variability 
between the different participating physicians and the coor-
dination of care levels, which complicates measurement of 
cost-effective interventions. However, and whether or not 
is conﬁ  rmed that a relationship exists between COPD and 
cardiovascular diseases, linked to the systemic inﬂ  amma-
tory component present in these patients, not only would it 
lead to an important advance in knowledge of the disease, 
Table 6 Comparison of different component of costs by tobacco use
Tobacco user N Mean Median 95% CI
Cost of hospitalization No 2468 654.79 419.15 (592.56–717.03)
Yes 8181 827.73* 561.51 (788.39–867.06)
Cost of drugs per year No 2468 476.91 529.25 (460.85–492.98)
Yes 8181 497.00* 529.25 (488.05–505.95)
Cost of visits to emergency rooms No 2468 119.42 52.26 (112.51–126.34)
Yes 8181 138.69* 104.52 (134.34–143.04)
Cost of diagnostic tests No 2468 120.30 97.32 (114.81–125.80)
Yes 8181 131.54* 97.32 (128.29–134.79)
Cost of visits to primary care No 2468 104.37 83.85 (100.55–108.18)
Yes 8181 107.79* 83.85 (105.70–109.88)
Cost of oxygen therapy per year No 2468 71.04 18.67 (60.79–81.28)
Yes 8181 100.260* 48.87 (93.64–106.87)
Cost of visits to pneumology No 2468 87.19 70.53 (83.21–91.17)
Yes 8181 95.33* 70.53 (92.97–97.68)
Cost of disability leave No 2468 41.07 6.04 (32.08–50.06)
Yes 8181 74.48* 26.36 (68.06–80.89)
Cost of pneumococcal vaccine No 2468 4.96 4.69 (4.68–5.23)
Yes 8181 4.48* 4.17 (4.34–4.63)
Cost of inﬂ  uenza vaccine No 2468 0.17 0.09 (0.15–0.19)
Yes 8181 0.22* 0.14 (0.21–0.23)
Total annual cost per COPD patient No 2468 1693.64 966.82 (1611.71–1775.57)
Yes 8181 1990.09* 1113.66 (1938.84–2041.33)
Notes: *p0.05 between tobacco users, differences between means not signiﬁ  cant when not stated.   Tobacco use: “Yes” includes current smokers and ex-smokers, “No” 
includes never smoked.
Abbreviations: CI, conﬁ  dence interval; COPD, chronic obstructive pulmonary disease.International Journal of COPD 2008:3(4) 708
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but would allow new treatment strategies to be designed 
that should act on various inﬂ  ammatory mediators, with the 
aim of modifying the risk of developing complications and 
reducing mortality (Sin et al 2003, 2005; Arroyo-Espliguero 
et al 2004).
The cost of management of COPD also depends, as was 
seen in this study, on the severity of airﬂ  ow obstruction 
measured by FEV1. Along this same line, Hilleman and 
colleagues (2000) showed that the severity of COPD was 
strongly correlated with health care resource utilization and 
consequently with the total cost of the disease. The average 
direct cost per patient per year over a 5-year follow-up 
was US$1,681 in ATS stage I (American Thoracic Society 
1995), $5,037 in stage II and $10,812 in stage III. Subse-
quently, Masa and colleagues (2004) also found an increase 
in costs as the severity of the disease increased: the cost of 
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severe COPD was 7 times that of mild COPD and 3 times 
that of moderate COPD. Despite the above, a more recent 
study showed that although airﬂ  ow obstruction is a valid 
predictor of health care resource utilization, its inﬂ  uence 
is small, and that the presence of comorbid conditions and 
symptoms of dyspnea are better predictors of costs (Mapel 
et al 2005).
Various authors have suggested the existence of other 
factors that may inﬂ  uence the cost of COPD (Miravitlles 
et al 2001; Soler et al 2001). One of these is health-related 
quality of life, which could explain why some COPD patients 
have a high utilization of health care resources and generate 
a high demand for these resources, as pointed out by Soler 
and colleagues (2001). Our study showed that the physical 
component of quality of life is one of the factors indepen-
dently inﬂ  uencing the overall cost of COPD. Previous studies 
that assessed the health status of patients with this disease 
in Spain found a worse quality of life in those who had 
more dyspnea, a greater degree of obstruction, were treated 
with more drugs, suffered more exacerbations, and required 
more visits to emergency rooms and hospital admissions 
(Miravitlles et al 2002, 2004; Sanjuás et al 2002; De Miguel 
et al 2004; Carrasco Garrido et al 2006).
Health care resource utilization is another of the major 
components of the cost of COPD, as shown in previous 
works (Mapel et al 2005). In this study, it was observed that 
among the factors determining the cost of COPD were the 
number of visits to the primary care physicians, the pneu-
mologists and emergency rooms, as well as the number of 
hospital admissions and their duration. Therefore, strategies 
for management of COPD should emphasize measures to 
control chronic symptoms and reduce exacerbations and 
hospitalizations, because the largest part of the cost of this 
disease is related to hospitalization. Furthermore, a previous 
study analyzing the costs of hospitalization found that the cost 
of the stay accounted for 70% of the total cost of care of the 
hospitalized COPD patient, whereas the cost of medical care, 
examinations or the drugs used was less than a third of the 
total (Serra 2002). In this context, optimization of resources 
does not lie in controlling the number of complementary 
examinations, but in reducing the number of days of hospital 
stay (Escarrabil 2003).
Table 7 Comparison of different costs by hospitalization
Hospital 
admission
N Mean Median 95% CI
Cost of hospitalization No 6015 0.00 0.00 (0.00–0.00)
Yes 2662 3173.56* 2010.00 (3088.66–3258.46)
Cost of drugs per year No 6015 465.71 365.00 (455.80–475.61)
Yes 2662 610.10* 529.25 (593.16–627.03)
Cost of visits to emergency rooms No 6015 80.69 60.48 (77.16–84.22)
Yes 2662 291.49* 209.04 (282.24–300.74)
Cost of diagnostic tests No 6015 98.87 97.32 (96.09–101.64)
Yes 2662 224.17* 194.64 (216.69–231.66)
Cost of visits to primary care No 6015 91.86 67.08 (89.84–93.88)
Yes 2662 158.70* 134.16 (154.17–163.23)
Cost of oxygen therapy per year No 6015 36.45 0.00 (31.68–41.21)
Yes 2662 261.56* 221.80 (244.47–278.65)
Cost of visits to pneumologists No 6015 71.65 70.53 (69.64–73.66)
Yes 2662 162.46* 141.06 (157.04–167.88)
Cost of disability leave No 6015 49.84 16.30 (44.41–55.27)
Yes 2662 105.47* 37.75 (90.65–120.28)
Cost of pneumococcal vaccine No 6015 4.23 3.89 (4.07–4.40)
Yes 2662 5.84* 5.67 (5.56–6.11)
Cost of inﬂ  uenza vaccine No 6015 0.22 0.00 (0.21–0.24)
Yes 2662 0.16* 0.00 (0.14–0.18)
Total annual cost per COPD patient No 6015 911.90 816.23 (895.86–927.95)
Yes 2662 5007.99* 4099.66 (4099.66–5111.82)
Note: *p  0.05 between hospital admitted patients, differences between means not signiﬁ  cant when not stated.
Abbreviations: CI, conﬁ  dence interval; COPD, chronic obstructive pulmonary disease.International Journal of COPD 2008:3(4) 710
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The indirect costs of COPD are more difﬁ  cult to assess. 
There are few articles in Spain that have assessed this com-
ponent and the results obtained varied widely, which has 
made their interpretation difﬁ  cult (Krief 1996; Izquierdo 
2003). It has been shown that patients with COPD have 
greater impairment of their ability to work and therefore are 
more likely to be disabled from work than those without this 
disease (Sin et al 2002). However, the estimated prevalence 
of work disability due to COPD remains controversial. 
Thus, Arancón (2002) indicated that asthma and COPD 
accounted for 3% of permanent work disabilities in Spain in 
the period 1999–2000, a ﬁ  gure that rose to 5.3% in the group 
of patients between 50 and 64 years of age. However, this 
ﬁ  gure is very far from that estimated by the Spanish Society 
of Pneumology and Chest Surgery (SEPAR), which indicated 
that 35% of permanent work disabilities are due to COPD 
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(Álvarez-Sala et al 2001; Pauwels et al 2001). Regardless of 
the actual prevalence, this study found that the duration of 
disability leaves was a factor that contributed independently 
to increasing the cost of this disease.
There are some limitations in our study. We excluded 
subjects with serious neurological and psychiatric diseases, 
and patients with recent exacerbations of COPD. As these 
disorders are expected to be associated with higher utilization 
of health care resources, we can not exclude an underestima-
tion of the real cost of COPD. In spite of these limitations, 
the data presented along with the predicted increase in the 
health care cost of COPD in the future, both in terms of its 
direct and indirect costs (Pauwels et al 2001), underscore the 
need for developing strategies aimed to optimize the use of 
resources devoted to the management of COPD, with special 
attention to early diagnosis.
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